TALENT: neoadjuvant Tdxd in HER2-low, HR+ early breast cancer - modest activity, pCR ~7%, not improved by adding anastrozole or sequencing chemotherapy. A useful reminder that HER2

Carmen Criscitiello· @CarmenCriscit · X·2026-10-23 20:12· 2 天前评分70

正文 · 原文

TALENT: neoadjuvant Tdxd in HER2-low, HR+ early breast cancer - modest activity, pCR ~7%, not improved by adding anastrozole or sequencing chemotherapy. A useful reminder that HER2-low is not the same as HER2-driven in the curative setting. #ESMO26 #ESMOAmbassadors @myESMO

201 浏览 · 7 赞 · 2 转发 · 0 回复

会议摘要

LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上

Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer

https://esmocongress.esmo.org

来源：Carmen Criscitiello · x.com